
Small-cell neuroendocrine disease associated with prostate cancer treatment appears to be more common than previously believed.

Your AI-Trained Oncology Knowledge Connection!


Small-cell neuroendocrine disease associated with prostate cancer treatment appears to be more common than previously believed.

In this article, we look at both metastatic hormone-sensitive and metastatic castration-resistant disease, and we highlight several of the emerging categories of advanced prostate cancer that have direct implications for patient management.

Treatment-emergent small-cell/neuroendocrine prostate cancer is likely to become of increasing clinical relevance in the era of widespread use of potent androgen receptor–targeted therapies.

Published: October 15th 2014 | Updated:

Published: June 15th 2017 | Updated:

Published: August 9th 2018 | Updated: